Close

NKG2D ligands

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The activating receptor NKG2D (natural-killer group 2, member D) and its ligands play an important role in the NK, γδ+ and CD8+ T-cell-mediated immune response to tumors. Ligands for NKG2D are rarely detectable on the surface of healthy cells and tissues, but are frequently expressed by tumor cell lines and in tumor tissues. It is evident that the expression levels of these ligands on target cells have to be tightly regulated to allow immune cell activation against tumors, but at the same time avoid destruction of healthy tissues. Many tumor cell lines and primary tumors from diverse tissue origins express NKG2D ligands. Ovarian carcinoma cells express low amounts of the NKG2D ligands MICA, ULBP1, and ULBP3, whereas ULBP2 was more highly expressed. NKG2D ligands were highly expressed in lymph node metastasis of stage I colorectal cancer samples, but they were expressed in lower amounts in Stage II, III, or IV tumors.

Associated Disease
  • CAR Vector Products

Loading...
  • Target Species:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-MZ230 Anti-NKG2D ligands NKG2D receptor h(CD3ζ) CAR, pCDCAR1 Human NKG2D receptor-CD3ζ Lentiviral T cell   Add to Cart   Datasheet
CAR-MZ231 Anti-NKG2D ligands, NKG2D receptor h(CD3ζ) CAR, pCDCAR1 Human NKG2D receptor-CD3ζ Retroviral NK cell   Add to Cart   Datasheet
CAR-MZ232 Anti-NKG2D ligands, NKG2D receptor h(DAP10-CD3ζ) CAR, pCDCAR1 Human DAP10-NKG2D receptor-CD3ζ Retroviral NK cell   Add to Cart   Datasheet
CAR-MZ233 Anti-NKG2D ligands, NKG2D receptor h(CD28-CD3ζ) CAR, pCDCAR1 Human NKG2D receptor-CD28-CD3ζ Retroviral NK cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.